medigraphic.com
ISSN 1561-3119 (Electronic)

2021, Number 3

<< Back Next >>

Rev Cubana Pediatr 2021; 93 (3)

A decade of care to patients with hypertrophic cardiomyopathy

Naranjo UAM, Fleitas RE, Aguilera SE

Language: Spanish
References: 34
Page: 1-16
PDF size: 396.24 Kb.


ABSTRACT

Introduction: Hypertrophic cardiomyopathy is a disease derived from autosomal dominant genetic alteration that causes an increase in the mass of the left ventricle, and can be obstructive or not. It is the leading cause of sudden death in young adults.
Objective: Show the prevalence of hypertrophic cardiomyopathy and its forms of presentation in the practice of the "William Soler" Pediatric Cardiocenter.
Methods: Retrospective, observational, longitudinal study of a case series. Demographic and clinical variables were summarized in the admissions made during 10 years of patients diagnosed with hypertrophic cardiomyopathy whom were analyzed as appropriate with qualitative and quantitative variable testing.
Results: 21 patients were identified; 12 with obstructive characteristics and 9 with non-obstructive ones. There was no predominance of sex. The average diagnostic age and clinical onset of patients with obstructive disease was significantly lower than the ages of patients without obstruction of the left outflow tract. Diagnosis was possible in more than 50% of cases by suspicion due to a murmur or by investigation. Surgical treatment allowed a significant reduction in the gradient of the left outflow tract. Propranolol was the most widely used beta-blocker according to international consensus. There were no deaths in the series studied.
Conclusions: Hypertrophic cardiomyopathy has a low prevalence in cardiopediatric practice. Early symptoms correspond to the obstructive variety. Early diagnosis and specific treatment ensure better quality and life expectancy for carriers of this condition.


REFERENCES

  1. Maron BJ, Maron MS, Semsarian C. Genetics in Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2012;60:705–15.

  2. Semsarian C, Ingles J, Maron MS, Maron BJ. New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–54.

  3. Arghami A, Dearani JA, Said SM, O’Leary PW, Schaff HV. Hypertrophic cardiomyopathy in children. Ann Cardiothorac Surg. 2017;6(4):376-85.

  4. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC): The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.

  5. Chia-Feng L, Wilson T. Epigenetics in Cardiac Hypertrophy and Heart Failure. J Am Coll Cardiol Basic Trans Science. 2019;4:976–93.

  6. 6 .Konst RE, Guzik TJ, Kaski J-C, Maas AHEM, Elias-Smale SE. The pathogenic role of coronary microvascular dysfunction in the setting of other cardiac or systemic conditions. Cardiovasc Res. 2020;116(4):817–28.

  7. Rigopoulos AG, Ali M, Abate E, Matiakis M, Melnyk H, Mavrogeni S, et al. Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy. Heart Fail Rev. 2019;24(3):359–66.

  8. Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy. Circ Res. 2017;121:749-70.

  9. Picarso J, Pérez L. Prevención de la muerte súbita cardiaca en Pediatría: el papel esncial del pediatra de Atención Primaria. Rev Pediatr Aten Primaria. 2015;17:77-86.

  10. Ministerio de Salud Pública. Anuario Estadístico de Salud. 2018. La Habana: Minsap; 2019.

  11. Argiro A, Zampieri M, Berteotti M, Marchi A, Tassetti L, Zocchi C, et al. Emerging medical treatment for hypertrophic cardiomyopathy. J Clin Med. 2021;10(5). doi. http://dx.doi.org/10.3390/jcm10050951

  12. Flores A, Paredes AM, Marrero RF, Rodríguez A, Valiente J. Miectomía septal Hipertrófica con obstrucción del tracto de salida del ventrículo izquierdo. Rev Cubana Cardiol Cirug Cardiovasc. 2015 [22/08/2018];21(1). Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/572

  13. Castro HJ, Zayas R, Fayad Y, Díaz PC, Dorticós B F, Prohías MJ. Estimulación bicameral en la miocardiopatía hipertrófica obstructiva subaórtica: información preliminar Rev Cubana Cardiol Cirug Cardiovasc.1999 [22/08/2018];13(1):13-8. Disponible en: http://bvs.sld.cu/revistas/car/vol13_1_99/car03199.htm

  14. La pirámide de población. Precisiones para su utilización. Rev Cubana Salud Pública. 2007[22/08/2018];33(2):6. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-34662007000400008

  15. Márquez MF, Ruíz-Siller TJ, Méndez-Ramos R, Karabut E, Aranda-Fraustro A, Jiménez-Becerra S. Miocardiopatía hipertrófica (MCH). Una revisión histórica y anatomopatológica. Gac Med Mex. 2016;152:697-702.

  16. Maurizi N, Passantino S, Spaziani G, Girolami F, Arretini MT. Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events. JAMA Cardiol. 2018;3(6). doi: http://dx.doi.org/101001/jamacardio20180789.

  17. Husser D, Ueberham L, Jacob J, Heuer D, Riedel-Heller S, Walker J, et al. Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany—An analysis of over 5 million patients. PLoS One. 2018;13(5):e0196612.

  18. Dávila F, Lewis AJ, Mogollón I, Mendoza F, Guatibonza DA. Cardiomiopatía hipertrófica: experiencia de 5 años. 2016. Rev Colomb Cardiol. 2017;24(3):297.e1-297.e8.

  19. Biswas DS, Kapoor M, Seth S, Bhargava B, Rao VR. Epidemiology of cardiomyopathy -A clinical and genetic study of hypertrophic cardiomyopathy: The EPOCH-H study. J Pract Cardiovasc Sci. 2015;1:143-9.

  20. Nguyen A, Schaff HV, Nishimura RA, Geske JB, Ackerman MJ, Bos JM, et al. Survival after myectomy for obstructive hypertrophic cardiomyopathy: What causes late mortality? Ann Thorac Surg. 2019;108(3):723–9.

  21. Mathew J, Zahavich L, Lafreniere-Roula M, Wilson J, George K, Benson L, et al. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. Clin Genet. 2018;93:310–9.

  22. Norrish G, Cantarutti N, Pissaridou E, Ridout DA, Limongelli G, Elliott PM. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. European Journal of Preventive Cardiology. 2017;24(11):1220-30.

  23. Hinek A, Teitell MA, Schoyer L, Allen W, Gripp KW, Hamilton R, et al. Myocardial storage of chondroitin sulfate-containing moieties in Costello syndrome patients with severe hypertrophic cardiomyopathy: Cardiomyopathy in Costello Syndrome. Am J Med Genet A. 2005;133A(1):1–12.

  24. Hakim K, Boussaada R, Hamdi I, Msaad H. Cardiac events in Costello syndrome: One case and a review of the literature. J Saudi Heart Assoc. 2014;26(2):105–9.

  25. Albakri A. Pediatric cardiomyopathies: A review of literature on clinical status and meta-analysis of diagnosis and clinical management methods. Pediatr Dimensions. 2018;3(2):1-14.

  26. Nakasuka K, Kitada S, Kawada Y, Kato M, Kikuchi S, Seo Y, et al. Future brady arrhythmia in patients with hypertrophic cardiomyopathy. Int J Cardiol Heart Vasc. 2021;33(100735):100735.

  27. Falasconi G, Pannone L, Slavich M, Margonato A, Fragasso G, Spoladore R. Atrial fibrillation in hypertrophic cardiomyopathy: pathophysiology, diagnosis and management. Am J Cardiovasc Dis. 2020;10(4):409–18.

  28. Castedo E, Cabo RA, Núñez I, Monguió E, Montero CG, Burgos R, et al. Tratamiento quirúrgico de la miocardiopatía hipertrófica obstructiva. Rev Española Cardiol. 2004;57(8):751-8.

  29. Morrow A. Hypertrophic subaortic stenosis. Operative methods utilized to relieve left ventricular outflow obstruction. J Thorac Cardiovasc Surg. 1978;76:423-30.

  30. Bansal N, Barach P, Amdani SM, Lipshultz SE. When is early septal myectomy in children with hypertrophic cardiomyopathy justified? Transl Pediatr. 2018;7(4):362–6.

  31. Li H, Deng L, Liu H, Chen S, Rao C, Tang Y, et al. Influence of operator volume on early outcomes of septal myectomy for isolated hypertrophic obstructive cardiomyopathy. J Thorac Dis. 2021;13(2):1090–9.

  32. Yang Q, Zhu C, Cui H, Tang B, Wang S, Yu Q, et al. Surgical septal myectomy outcome for obstructive hypertrophic cardiomyopathy after alcohol septal ablation. J Thorac Dis. 2021;13(2):1055–65.

  33. Sp MBJ, Mj A, Sa C, C S, M ME, Km S, et al. Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillators in Children and Adolescents With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2013;61:1527–35.

  34. Magnusson P, Jonsson J, Mörner S, Fredriksson L. Living with hypertrophic cardiomyopathy and an implantable defibrillator. BMC Cardiovasc Disord. 2017;17(1). doi: http://dx.doi.org/10.1186/s12872-017-0553-y




2020     |     www.medigraphic.com